Test Code FAPM Fatty Acid Profile, Mitochondrial (C8-C18), Serum
Reporting Name
Fatty Acid Profile, Mitochondrial,SUseful For
Biochemical diagnosis of inborn errors of mitochondrial fatty acid oxidation, including deficiencies of medium-chain acyl-Co-A dehydrogenase, long-chain 3-hydroxyacyl-Co-A dehydrogenase, very long-chain acyl-Co-A dehydrogenase, and glutaric acidemia type 2
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
SerumNecessary Information
1. Patient's age is required.
2. Include information regarding treatment, family history, and tentative diagnosis.
Specimen Required
Patient Preparation:
1. For nutritional assessment, patient should fast overnight (12-14 hours); for patients with a suspected fatty acid oxidation disorder, collect immediately before next feeding as fasting is contraindicated.
2. Patient must not consume any alcohol for 24 hours before the specimen collection.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Â Serum gel
Acceptable: Â Red Top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial.
Specimen Minimum Volume
0.15 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Frozen (preferred) | 92 days | |
Refrigerated | 72 hours |
Reference Values
Octanoic Acid, C8:0
<1 year: 7-63 nmol/mL
1-17 years: 9-41 nmol/mL
≥18 years: 8-47 nmol/mL
Decenoic Acid, C10:1
<1 year: 0.8-4.8 nmol/mL
1-17 years: 1.6-6.6 nmol/mL
≥18 years: 1.8-5.0 nmol/mL
Decanoic Acid, C10:0
<1 year: 2-62 nmol/mL
1-17 years: 3-25 nmol/mL
≥18 years: 2-18 nmol/mL
Lauroleic Acid, C12:1
<1 year: 0.6-4.8 nmol/mL
1-17 years: 1.3-5.8 nmol/mL
≥18 years: 1.4-6.6 nmol/mL
Lauric Acid, C12:0
<1 year: 6-190 nmol/mL
1-17 years: 5-80 nmol/mL
≥18 years: 6-90 nmol/mL
Tetradecadienoic Acid, C14:2
<1 year: 0.3-6.5 nmol/mL
1-17 years: 0.2-5.8 nmol/mL
≥18 years: 0.8-5.0 nmol/mL
Myristoleic Acid, C14:1
<1 year: 1-46 nmol/mL
1-17 years: 1-31 nmol/mL
≥18 years: 3-64 nmol/mL
Myristic Acid, C14:0
<1 year: 30-320 nmol/mL
1-17 years: 40-290 nmol/mL
≥18 years: 30-450 nmol/mL
Hexadecadienoic Acid, C16:2
<1 year: 4-27 nmol/mL
1-17 years: 3-29 nmol/mL
≥18 years: 10-48 nmol/mL
Palmitoleic Acid, C16:1w7
<1 year: 20-1,020 nmol/mL
1-17 years: 100-670 nmol/mL
≥18 years: 110-1,130 nmol/mL
Palmitic Acid, C16:0
<1 year: 720-3,120 nmol/mL
1-17 years: 960-3,460 nmol/mL
≥18 years: 1,480-3,730 nmol/mL
Linoleic Acid, C18:2w6
≤31 days: 350-2,660 nmol/mL
32 days-11 months: 1,000-3,300 nmol/mL
1-17 years: 1,600-3,500 nmol/mL
≥18 years: 2,270-3,850 nmol/mL
Oleic Acid, C18:1w9
<1 year: 250-3,500 nmol/mL
1-17 years: 350-3,500 nmol/mL
≥18 years: 650-3,500 nmol/mL
Stearic Acid, C18:0
<1 year: 270-1,140 nmol/mL
1-17 years: 280-1,170 nmol/mL
≥18 years: 590-1,170 nmol/mL
Day(s) Performed
Monday through Friday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82725
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
FAPM | Fatty Acid Profile, Mitochondrial,S | 43675-8 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
17007 | Octanoic Acid, C8:0 | 35145-2 |
17008 | Decenoic Acid, C10:1 | 35147-8 |
17009 | Decanoic Acid, C10:0 | 35146-0 |
17010 | Lauroleic Acid, C12:1 | 35151-0 |
17011 | Lauric Acid, C12:0 | 35150-2 |
17012 | Tetradecadienoic Acid, C14:2 | 35148-6 |
17013 | Myristoleic Acid, C14:1 | 35158-5 |
17014 | Myristic Acid, C14:0 | 35157-7 |
17015 | Hexadecadienoic Acid, C16:2 | 35154-4 |
17016 | Palmitoleic Acid, C16:1w7 | 35162-7 |
17017 | Palmitic Acid, C16:0 | 35161-9 |
17018 | Linoleic Acid, C18:2w6 | 35165-0 |
17019 | Oleic Acid, C18:1w9 | 35166-8 |
17020 | Stearic Acid, C18:0 | 35149-4 |
17055 | Interpretation | 59462-2 |
Interpretation
Fatty acid oxidation disorders are recognized on the basis of disease-specific metabolite patterns that are correlated to the results of other investigations in plasma (carnitine, acylcarnitines) and urine (organic acids, acylglycines).
Clinical Reference
1. Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Ann Rev Physiol. 2002;64:477-502
2. Kang E, Kim YM, Kang, M, et al. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening. BMC Pediatr. 2018;18(1):103
Report Available
3 to 5 daysMethod Name
Gas Chromatography Mass Spectrometry (GC-MS) Stable Isotope Dilution
Testing Algorithm
For more information see Epilepsy: Unexplained Refractory and/or Familial Testing Algorithm
Special Instructions
Forms
If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.